Evidence map›Paper›PMID 34370393›Full record

ArticleInternational journal of rheumatic diseases2021

COVID-19 pneumonia can cause irreversible lung damage in dermatomyositis with pre-existing interstitial lung disease.

Satoshi Hama, Mitsuhiro Akiyama, Tatsuya Shimada, Misako Higashida-Konishi, Hiroshi Takei, Keisuke Izumi, Hisaji Oshima, Yutaka Okano

Open access · bronzeAbstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Satoshi HamaDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Mitsuhiro AkiyamaDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5075-8977
Tatsuya ShimadaDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Misako Higashida-KonishiDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8712-3852
Hiroshi TakeiDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Keisuke IzumiDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8597-0759
Hisaji OshimaDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Yutaka OkanoDepartment of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Keio University · JPTokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

SARS-CoV-2AgedComorbidityCOVID-19DermatomyositisHumansLungLung Diseases, InterstitialMaleTomography, X-Ray ComputedCOVID-19dermatomyositisinterstitial lung diseaseSARS-CoV-2

Identifiers

PMID34370393
PMCPMC8441718
OpenAlexW3188253097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.